Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The ... Read More
Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More
Lupin, Enzene Biosciences to launch cancer drug Cetuximab biosimilar in India
Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India. Cetuximab is ... Read More
Cue Biopharma gets FDA fast track status for CUE-101 in HPV16+ R/M HNSCC
Cue Biopharma has been granted fast track designation for CUE-101 from the US Food and Drug Administration (FDA) for the treatment of a type of ... Read More
PDS Biotechnology gets FDA fast track status for PDS0101
PDS Biotechnology has secured fast track designation to its PDS0101 in combination with Merck’s KEYTRUDA (pembrolizumab) from the US Food and Drug Administration (FDA) for ... Read More
ImmVira wraps up first dosing for MVR-T3011 in US and China
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product - MVR-T3011 intratumoral injection in phase 2 clinical trials both ... Read More
MiraDx to enroll patients for non-tumor based microRNA clinical trial
MicroRNA clinical trial : MiraDx, a Los Angeles-based molecular genetics company, has initiated patient enrollment in collaboration with UCLA for the non-tumor based microRNA biomarker-driven ... Read More
FDA removes clinical hold on Advaxis’ Axalimogene Filolisbac, Durvalumab combo trial
Advaxis, a biotech firm based in New Jersey, announced a significant regulatory update as the U.S. Food and Drug Administration (FDA) has lifted the clinical ... Read More